

Agenda for Episurf Medical's Digital Capital Markets Day 2020

Episurf Medical AB (Nasdaq: EPIS B) invites investors, analysts and media to the Group's Digital Capital Markets Day on Tuesday September 15, 2020 at 13:00 CEST – 16:00 CEST.

The purpose of the Capital Markets Day is to increase the understanding of Episurf Medical's business, technology, clinical results and future opportunities.

Agenda

Section 1, 13:00 CEST

Introduction, strategy and future opportunities, Pål Ryfors, CEO
Corporate, Veronica Wallin, CFO
Regulatory and IP, Katarina Flodström, COO

Section 2, approximately 13:50 CEST

Cartilage surgery: History and treatment options, Prof. Pieter Emans, Maastricht UMC+, Maastricht University, the Netherlands
Episealer® Clinical activities, Fredrik Zetterberg, Marketing Director
The Episealer® technology, technique and clinical results, Dr. med. Johannes Holz, Park-Klinik Manhagen, Orthocentrum, Hamburg, Germany
The EPIC-Knee Study, Katarina Flodström, COO

Section 3, approximately 15:10 CEST

The Episealer® Talus and Osteotomy guide, Prof. Niek van Dijk, University of Amsterdam, the Netherlands, The FIFA Medical Centers of Excellence, Madrid Spain
Summary, Pål Ryfors, CEO
Q&A

The digital event is accessible at the link below, or through www.episurf.com or www.redeye.se. No pre-registration is necessary, however, you need to sign-up at www.redeye.se (easy and free of charge) when accessing the event live. It will be possible to submit questions during the event through ir@episurf.com or through Redeye's event page.

A webcast of the event will also be available after the event on Episurf Medical's website.

<https://www.redeye.se/events/791876/kapitalmarknadsdag-episurf>

Welcome!

Episurf Medical, Board of Directors and Management Team

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's piFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.